Table 1

Baseline demographic and clinical characteristics

Normal baseline CRP
(<5 mg/L)
Elevated baseline CRP
(≥5 mg/L)
Pooled secukinumab
150 mg (N=72)
Pooled placebo
(N=71)
Pooled secukinumab
150 mg (N=125)
Pooled placebo
(N=124)
Age (years), mean (SD)42.3 (10.5)45.3 (13.2)39.9 (12.7)42.2 (12.3)
Male, n (%)39 (54.2)47 (66.2)91 (72.8)93 (75.0)
Weight (kg), mean (SD)74.5 (14.6)76.4 (13.8)79.2 (18.4)79.0 (15.3)
Caucasian, n (%)* 50 (69.4)51 (71.8)88 (70.4)100 (80.6)
Time since AS diagnosis (years), mean (SD)5.9 (7.2)8.1 (9.9)7.2 (7.5)7.3 (8.3)
Positive for HLA-B27, n (%)44 (61.1)53 (74.6)99 (79.2)95 (76.6)
TNFi-naïve, n (%)52 (72.2)39 (54.9)84 (67.2)94 (75.8)
Concomitant methotrexate use, n (%)9 (12.5)7 (9.9)16 (12.8)17 (13.7)
hsCRP (mg/L), median (minimum‒maximum)2.1 (0.2‒4.9)1.9 (0.2‒4.9)16.8 (5.0‒237.0)14.9 (5.0‒146.8)
Total BASDAI score, mean (SD)6.7 (1.4)6.6 (1.6)6.3 (1.6)6.6 (1.4)
PtGA of disease activity (0‒100 mm), mean (SD)†68.0 (17.4)66.9 (19.3)63.7 (19.1)68.4 (16.7)
  • *Race was self-assessed.

  • †Disease activity was scored on a visual-analog scale from 0 (no disease activity) to 100 mm (the most severe disease activity).

  • AS, ankylosing spondylitis; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; CRP, C-reactive protein; HLA, human leucocyte antigen; N, number of patients in this pooled study; PtGA, patients global assessment; TNFi, tumor necrosis factor inhibitor; hsCRP, high sensitivity CRP.